2000-2022年美国成人糖尿病患者降糖药物人均支出的全国趋势
该研究基于医疗支出面板调查数据,分析2000-2022年美国≥18岁自报糖尿病成人降糖药物人均支出趋势。人均总支出从2000年856美元增至2022年3725美元,增幅335%;2000-2012年每年增29美元,之后每年增224美元。新型非胰岛素药物支出大幅上升,主要驱动因素为使用者数量增加。
要点
- 人均降糖药支出22年间增长335%,2012年后加速上升。
- 新型非胰岛素药物支出显著增加,使用者数量是主要驱动因素。
- 传统口服药及人胰岛素支出下降,类似物胰岛素支出2016年后趋于平稳。
核心结论
- 美国成人糖尿病患者降糖药物人均支出在2000-2022年间大幅上升,新型药物支出增长显著。
研究设计与样本
- 基于医疗支出面板调查(MEPS)数据,分析2000-2022年≥18岁自报糖尿病成人降糖药物人均支出。
- 按年龄、种族/民族、收入和保险状态进行亚组分析,并使用Joinpoint回归识别趋势变化。
- 药物分为较老口服药、较新非胰岛素药、人胰岛素和类似物胰岛素,支出调整至2022年美元。
主要发现
- 人均总支出从2000年856美元增至2022年3725美元,增幅335%。
- 2000-2012年支出每年增加29美元,之后每年增加224美元。
- 较新非胰岛素药物支出大幅增加,较老口服药和人胰岛素支出下降。
- 类似物胰岛素支出初期上升,2016年后趋于平稳。
- 较新高成本疗法的支出上升趋势主要由使用者数量增加驱动。
临床怎么用
- 关注新型降糖药物支出增长对医保和患者可负担性的影响。
- 处方决策时需权衡新型药物的临床获益与费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Expenditures on glucose-lowering prescriptions may have changed because of the introduction of new medication classes and changes in insurance policies. This study analyzed national trends in per capita expenditures on glucose-lowering medications among U.S. adults with diabetes during 2000-2022. RESEARCH DESIGN AND METHODS: Using Medical Expenditure Panel Surveys data, we analyzed annual per capita expenditures on glucose-lowering medications among people aged ≥18 years with self-reported diabetes. Expenditures were calculated overall and by subgroups defined by age, race and ethnicity, income, and insurance status. Medications were grouped as older oral agents (metformin, sulfonylureas, thiazolidinediones, α-glucosidase inhibitors, meglitinides), newer noninsulin agents (dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, amylin analogs, combination products), human insulin, and analog insulin. Joinpoint regression was used to identify trend changes. We also estimated the change in number of users and expenditure per user for each medication category. Expenditures were adjusted to 2022 U.S. dollars. RESULTS: Total per capita expenditures on glucose-lowering medications increased by 335%, from $856 in 2000 to $3,725 in 2022. Expenditures rose by $29 per year during 2000-2012, then accelerated by $224 annually. Expenditures increased substantially on newer noninsulin agents while declining on older oral agents, and human insulin expenditures declined. Analog insulin expenditures rose initially but plateaued after 2016. The upward trend in newer high-cost therapies was primarily driven by an increased number of users. CONCLUSIONS: Per capita expenditures on newer medications have risen markedly. Identifying key drivers of these expenditures may enhance affordability and access to effective diabetes treatments.
引用
- Wang Y, Bullard KM, Zhang P, et al. National Trends in Expenditures on Glucose-Lowering Medications in U.S. Adults With Diabetes: 2000-2022. Diabetes Care. 2026. PMID: 41701609. doi:10.2337/dc25-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。